Immunotherapy provides significantly increased rates of survival in patients with Lymphomatoid Granulomatosis

A groundbreaking study suggests that a new immunotherapy-based approach for low-grades of lymphomatoid granulomatosis, a rare precancerous condition induced by Epstein-Barr virus infection, is effective and improves survival compared to chemotherapy and corticosteroids.

“In the phase 2 trial, led by researchers in the Center for Cancer Research at the National Cancer Institute (NCI), part of NIH, patients treated with interferon alfa-2b lived for a median of about 20 years. By contrast, past studies reported a median survival of less than two years for people with lymphomatoid granulomatosis.”

SOURCE:    https://www.nih.gov/news-events/news-releases/nih-study-finds-immunotherapy-substantially-increases-survival-people-lymphomatoid-granulomatosis 

CREDITS: NATIONAL INSTITUTES OF HEALTH; April 19, 2023